Story perspectives

New RSV Vaccines Show Promise for Infant Protection

11/6/2025

32 3

Summary

Story summary

Enanta's EDP-323 shows promise by significantly reducing symptoms and viral load.
Pfizer's Abrysvo demonstrated 75% effectiveness against RSV-related hospitalizations, strengthening its market position.
Moderna targets the immunocompromised with its mRNA vaccine, mRESVIA, expanding options for vulnerable patients.
Merck's Enflonsia offers a single-dose alternative for infants, contrasting with Beyfortus, which requires weight-based dosing.
Maternal vaccination provides a dual approach for infant protection and signals a shift toward combination strategies.

1 of 1

Story summary

Enanta's EDP-323 shows promise by significantly reducing symptoms and viral load.
Pfizer's Abrysvo demonstrated 75% effectiveness against RSV-related hospitalizations, strengthening its market position.
Moderna targets the immunocompromised with its mRNA vaccine, mRESVIA, expanding options for vulnerable patients.
Merck's Enflonsia offers a single-dose alternative for infants, contrasting with Beyfortus, which requires weight-based dosing.
Maternal vaccination provides a dual approach for infant protection and signals a shift toward combination strategies.